About: Asian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease (IBD) Working Party guidelines on IBD management during the COVID‐19 pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Asian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease (IBD) Working Party guidelines on IBD management during the COVID‐19 pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Asian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease (IBD) Working Party guidelines on IBD management during the COVID‐19 pandemic
Creator	Chen, Min Leung, Wai Ahuja, Vineet Banerjee, Rupa Hilmi, Ida Hisamatsu, Tadakazu Leong, Rupert Ling, Khoon Ooi, Choon Pisespongsa, Pises Simadibrata, Marcellus Sollano, Jose Wei, Shu Wu, Kai Affendi, Raja Ali, Raja Byong, ∥ Chuah, Wei Deng, § Govind, ∥∥ Makharia, K Ng, Chien Ran, Hua Sai, ‡ Siew, ∥ Wu, Chyang Ye, Duk Zhi, ‡
Source	Medline; PMC; WHO
abstract	The COVID‐19 pandemic, secondary to SARS‐CoV‐2, has resulted in high mortality and morbidity worldwide. As inflammatory bowel disease (IBD) is a chronic disease, and most patients are on long‐term immunosuppressive agents, there is understandable concern, particularly in terms of therapy. In view of this, experts in IBD across the Asia Pacific region were invited to put together recommendations based on their experience and the currently available data. In general, most IBD therapies (with a few exceptions) can be continued safely, and the general consensus is that maintaining disease control should remain the main principle of management. In addition, social distancing measures and the appropriate use of personal protective equipment should be strictly adhered to. During the current pandemic, face‐to‐face clinic follow ups and non‐urgent procedures should be kept to a minimum.
has issue date	2020-06-05(xsd:dateTime)
bibo:doi	10.1002/jgh3.12362
bibo:pmid	32514431
has license	cc-by
sha1sum (hex)	3a6f755d23ec584a80cd1f767b02bb316cfda5ce
schema:url	https://doi.org/10.1002/jgh3.12362
resource representing a document's title	Asian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease (IBD) Working Party guidelines on IBD management during the COVID‐19 pandemic
has PubMed Central identifier	PMC7273734
has PubMed identifier	32514431
schema:publication	JGH Open
resource representing a document's body	covid:3a6f755d23ec584a80cd1f767b02bb316cfda5ce#body_text
is schema:about of	named entity 'procedures' named entity 'principle' named entity 'morbidity' named entity 'inflammatory bowel disease (IBD)' named entity 'chronic disease' named entity 'therapy' named entity 'management' named entity 'Asian' named entity 'Pacific Association' named entity 'BASED' named entity 'IS A' named entity 'CHRONIC DISEASE' named entity 'IBD' named entity 'patients' named entity 'IBD' named entity 'During' named entity 'disease' named entity 'inflammatory bowel disease' named entity 'immunosuppressive agents' named entity 'IBD' named entity 'chronic disease' named entity 'APAGE' named entity 'IBD' named entity 'cardiovascular' named entity 'COVID' named entity 'loss of appetite' named entity 'MERS' named entity 'corticosteroids' named entity 'biological agent' named entity 'Noninvasive' named entity 'IBD' named entity 'upper airways' named entity 'shortness of breath' named entity 'Infection' named entity 'epithelial cells' named entity 'asymptomatic' named entity 'IBD' named entity 'SARS-CoV-2' named entity 'Crohn's disease' named entity 'MERS' named entity 'SARS-CoV-2' named entity 'methotrexate' named entity 'public health' named entity 'infection' named entity 'respiratory symptoms' named entity 'point-of-care test' named entity 'COVID-19' named entity 'baricitinib' named entity 'COVID' named entity 'infection' named entity 'adalimumab' named entity 'facial mask' named entity 'enteral nutrition' named entity 'tofacitinib'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software